How patient frailty determines lung protection benefits in personalized diabetes care
In a significant research advancement that may help inform treatment strategies for millions of patients worldwide, a research team led by Prof. Fei-Yuan Hsiao of National Taiwan University and Prof. Liang-Kung Chen of National Yang-Ming Chiao Tung University has provided important new insights into a critical clinical question: “Which diabetes medications may offer better lung outcomes for patients with both diabetes and COPD—and does patient frailty matter?”